JSPR Stock Analysis: Buy, Sell, or Hold?
JSPR - Jasper Therapeutics, Inc. Common Stock
$0.72
0.02 (3.59%)
â˛
5d:
-9.38%
30d:
-1.8%
90d:
-17.95%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When JSPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: JSPR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: JSPR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: JSPR is currently trading at $0.72, which is considered fair relative to its 30-day fair value range of $0.64 to $0.81.
Technical Outlook: Technically, JSPR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.97. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: JSPR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.38 (+930.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JSPR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.97. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: JSPR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.38 (+930.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.64 -
$0.81
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 930.0% below Wall St target ($7.38)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.64 -
$0.81
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.97
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.28
Wall Street Target
$7.38
(+930.0%)
Share & Embed Analysis
Last updated: August 23, 2026 9:04 PM ET
Data refreshes hourly during market hours. Next update: 10:04 PM
Data refreshes hourly during market hours. Next update: 10:04 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JSPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
